Journal
AMERICAN JOURNAL OF PATHOLOGY
Volume 174, Issue 6, Pages 2347-2356Publisher
ELSEVIER SCIENCE INC
DOI: 10.2353/ajpath.2009.081037
Keywords
-
Categories
Funding
- National Institutes of Health [CA112270]
- National Leiomyosarcoma Foundation
- LMSarcoma Direct Research Foundation
- British Columbia Cancer Agency's Musculoskeletal Tumor Group
Ask authors/readers for more resources
previously, we showed that the presence of high numbers of macrophages correlates with poor prognosis in nongynecological leiomyosarcoma ill In gynecological LMS, a similar trend was noted but did not reach statistical significance. Colony-stimulating factor-1 (CSF1) is a major chemoattractant for macrophages. Here we show that in a subset of LMS cases, CSF1 is expressed by the malignant cells. Previously, we found that CSF1 is translocated and highly expressed in tenosynovial giant cell tumors (TGCTs), and this observation allowed us to identify genes that showed a coordinate expression with CSF1. Here, we evaluated the expression of CSF1 and TGCT-associated proteins in 149 cases of LMS. The coordinate expression of CSF1 and three TGCT-associated proteins (CD163, FCGR3a, and CTSL1) identified cases with poor prognosis in both gynecological LMS (P = 0.00006) and nongynecological LMS (P = 0.03). In gynecological LMS, the coordinate expression of these four markers, was the only independent prognosticator in multivariate analysis (hazard ratio, 4.2; 95% CI, 1.12 to 16; P = 0.03). Our findings indicate that CSF1 may play an important role in the clinical behavior of LMS that may open a window for new therapeutic reagents. (Am J Pathol 2009, 174:2347-2356; DOI: 10.2353/ajpath.2009.081037)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available